Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Germany-based drug discovery company Proteros biostructures, has signed a research services agreement with Belgium-based biotechnology company UCB, pursuant to which, Proteros will support the structure-based discovery of small molecule drugs.
Subscribe to our email newsletter
In the initial stage of the program, Proteros will leverage its expertise in gene-to-structure projects and its proprietary technologies to solve the three dimensional structure of an undisclosed target together with its related proteins.
After the establishment of these crystallography systems, Proteros will screen fragments and compounds supplied by UCB with the objective of solving high resolution X-ray structures of the fragments and compounds to confirm the binding modes to the proteins, and therefore facilitating the medicinal chemistry and optimization of small molecules. The financial terms of the fixed research fees and milestones are not disclosed.
Torsten Neuefeind, CEO of Proteros, said: “We are very pleased to extend our successful relationship which we first entered in 2007, and now to be considered a key partner for UCB in this important project with UCB New Medicines.”